IGF Oncology, LLC

PINE SPRINGS, MN · CIK 0001745915 · Biotech · Private

Novel small-molecule cancer drugs targeting IGF signaling pathways

igfoncology.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$2.4M
1 Form D · Jul 2018
99 months since last filing
Contracts
—
No federal contracts on record
Patents
9
5 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$2,359,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1945PanTheryx, Inc.—$84M
1946Vero Biotech Inc.—$84M
1947RAKTA THERAPEUTICS, INC.——
1948IGF Oncology, LLC—$2.4M
1949GENECENTRIX INC.——
1950SCALED MICROBIOMICS, LLC——
1951RYLTI, LLC—$2.3M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • Hugh McTavishExecutive Officer

Patents

USPTO · 5 granted of 9

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.